Condition: Colorectal Cancer · Colorectal Adenocarcinoma · Rectal Adenocarcinoma · Sponsor: Gruppo Oncologico del Nord-Ovest
The aim of this study is to evaluate the activity of first-line trastuzumab-deruxtecan, capecitabine and bevacizumab in terms of overall response rate for patients with HER-2 positive metastatic/locally advanced unresectable colorectal cancer
This description comes directly from the study's public registry record.
Filippo Pietrantonio, MD · 0039-3407683357 · filippo.pietrantonio@istitutotumori.mi.it
Federica M Palermo, Dr · chimerastudy@istitutotumori.mi.it
Always discuss trial participation with your own doctor first.
| Hopital Prive Jean Mermoz | Lyon, France | Recruiting |
| Hôpital La Timone - APHM | Marseille, France | Recruiting |
| Hopital Saint Louis | Paris, France | Recruiting |
| Centre Hospitalier Universitaire Reims | Reims, France | Recruiting |
| Groupe Hospitalier Rance Emeraude | St-Malo, France | Recruiting |
| Charite Universitaetsmedizin | Berlin, Germany | Recruiting |
| Krankenhaus Nordwest | Frankfurt, Germany | Recruiting |
| Istituto Tumori Bari Giovanni Paolo II | Bari, Bari, Italy | Recruiting |
| A.O.U Careggi | Florence, Firenze, Italy | Recruiting |
| Istituto Europeo Di Oncologia S.r.l. | Milan, Italy, Italy | Recruiting |
| Azienda Unita Sanitaria Locale Della Romagna | Ravenna, Italy, Italy | Recruiting |
| Humanitas Mirasole S.p.A. | Rozzano, Italy, Italy | Recruiting |
+ 16 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07407465